Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Roche Media News
Get the latest updates from Roche Media News directly as they happen.
Follow now 327 followers
Latest posts
Last updated 2 days ago
Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
2 days ago
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
11 days ago
Group sales grew by 7%1 at constant exchange rates (CER; 2% in...
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
13 days ago
A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight...
FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma
about 2 months ago
Lunsumio VELO reduces administration time from 2-4 hours to approximately one minuteAvailability...
Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu
2 months ago
With this approval, Roche’s automated mass spectrometry platform now offers the industry’s...
Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
2 months ago
Giredestrant is the only oral SERD to show superior invasive disease-free survival...
Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark
2 months ago
The new PCR test aids in the diagnosis of infectious causes of...
European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis
2 months ago
Approval based on phase II NOBILITY and phase III REGENCY studies showing...
Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas
2 months ago
Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed...
Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study
2 months ago
Overall survival was twice as long for people treated with Columvi in...
Roche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis)
2 months ago
The point-of-care test delivers PCR-accurate results in just 15 minutes, enabling healthcare...
European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma
3 months ago
Lunsumio provides high rates of deep and long-lasting responses in third-line and...